145 related articles for article (PubMed ID: 31518438)
1. BTK inhibitors synergise with 5-FU to treat drug-resistant TP53-null colon cancers.
Lavitrano M; Ianzano L; Bonomo S; Cialdella A; Cerrito MG; Pisano F; Missaglia C; Giovannoni R; Romano G; McLean CM; Voest EE; D'Amato F; Noli B; Ferri GL; Agostini M; Pucciarelli S; Helin K; Leone BE; Canzonieri V; Grassilli E
J Pathol; 2020 Feb; 250(2):134-147. PubMed ID: 31518438
[TBL] [Abstract][Full Text] [Related]
2. p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.
Giordano F; Vaira V; Cortinovis D; Bonomo S; Goedmakers J; Brena F; Cialdella A; Ianzano L; Forno I; Cerrito MG; Giovannoni R; Ferri GL; Tasciotti E; Vicent S; Damarco F; Bosari S; Lavitrano M; Grassilli E
J Exp Clin Cancer Res; 2019 Jun; 38(1):260. PubMed ID: 31200752
[TBL] [Abstract][Full Text] [Related]
3. p65BTK Is a Novel Biomarker and Therapeutic Target in Solid Tumors.
Grassilli E; Cerrito MG; Bonomo S; Giovannoni R; Conconi D; Lavitrano M
Front Cell Dev Biol; 2021; 9():690365. PubMed ID: 34164404
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of GSK3B bypass drug resistance of p53-null colon carcinomas by enabling necroptosis in response to chemotherapy.
Grassilli E; Narloch R; Federzoni E; Ianzano L; Pisano F; Giovannoni R; Romano G; Masiero L; Leone BE; Bonin S; Donada M; Stanta G; Helin K; Lavitrano M
Clin Cancer Res; 2013 Jul; 19(14):3820-31. PubMed ID: 23729362
[TBL] [Abstract][Full Text] [Related]
5. The use of protein array to identify targetable receptor tyrosine kinases for treatment of human colon cancer.
Morishita A; Gong J; Nomura T; Yoshida H; Izuishi K; Suzuki Y; Kushida Y; Haba R; D'Armiento J; Masaki T
Int J Oncol; 2010 Oct; 37(4):829-35. PubMed ID: 20811704
[TBL] [Abstract][Full Text] [Related]
6. The sirtuin inhibitor tenovin-6 upregulates death receptor 5 and enhances cytotoxic effects of 5-fluorouracil and oxaliplatin in colon cancer cells.
Ueno T; Endo S; Saito R; Hirose M; Hirai S; Suzuki H; Yamato K; Hyodo I
Oncol Res; 2013; 21(3):155-64. PubMed ID: 24512730
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous use of erythropoietin and LFM-A13 as a new therapeutic approach for colorectal cancer.
Tankiewicz-Kwedlo A; Hermanowicz JM; Domaniewski T; Pawlak K; Rusak M; Pryczynicz A; Surazynski A; Kaminski T; Kazberuk A; Pawlak D
Br J Pharmacol; 2018 Mar; 175(5):743-762. PubMed ID: 29160911
[TBL] [Abstract][Full Text] [Related]
8. CRISPR screens identify cholesterol biosynthesis as a therapeutic target on stemness and drug resistance of colon cancer.
Gao S; Soares F; Wang S; Wong CC; Chen H; Yang Z; Liu W; Go MYY; Ahmed M; Zeng Y; O'Brien CA; Sung JJY; He HH; Yu J
Oncogene; 2021 Dec; 40(48):6601-6613. PubMed ID: 34621019
[TBL] [Abstract][Full Text] [Related]
9. A novel oncogenic BTK isoform is overexpressed in colon cancers and required for RAS-mediated transformation.
Grassilli E; Pisano F; Cialdella A; Bonomo S; Missaglia C; Cerrito MG; Masiero L; Ianzano L; Giordano F; Cicirelli V; Narloch R; D'Amato F; Noli B; Ferri GL; Leone BE; Stanta G; Bonin S; Helin K; Giovannoni R; Lavitrano M
Oncogene; 2016 Aug; 35(33):4368-78. PubMed ID: 26804170
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of chemosensitivity in 5-fluorouracil-resistant colon cancer cells with carcinoembryonic antigen-specific RNA aptamer.
Lee JH; Lee SW
Mol Biol Rep; 2019 Aug; 46(4):3835-3842. PubMed ID: 31028570
[TBL] [Abstract][Full Text] [Related]
11. Chidamide and 5-flurouracil show a synergistic antitumor effect on human colon cancer xenografts in nude mice.
Liu L; Qiu S; Liu Y; Liu Z; Zheng Y; Su X; Chen B; Chen H
Neoplasma; 2016; 63(2):193-200. PubMed ID: 26774139
[TBL] [Abstract][Full Text] [Related]
12. Targeting Histone Chaperone FACT Complex Overcomes 5-Fluorouracil Resistance in Colon Cancer.
Song H; Zeng J; Roychoudhury S; Biswas P; Mohapatra B; Ray S; Dowlatshahi K; Wang J; Band V; Talmon G; Bhakat KK
Mol Cancer Ther; 2020 Jan; 19(1):258-269. PubMed ID: 31575655
[TBL] [Abstract][Full Text] [Related]
13. Targeting the DNA replication checkpoint by pharmacologic inhibition of Chk1 kinase: a strategy to sensitize APC mutant colon cancer cells to 5-fluorouracil chemotherapy.
Martino-Echarri E; Henderson BR; Brocardo MG
Oncotarget; 2014 Oct; 5(20):9889-900. PubMed ID: 25301724
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of caspases primes colon cancer cells for 5-fluorouracil-induced TNF-α-dependent necroptosis driven by RIP1 kinase and NF-κB.
Oliver Metzig M; Fuchs D; Tagscherer KE; Gröne HJ; Schirmacher P; Roth W
Oncogene; 2016 Jun; 35(26):3399-409. PubMed ID: 26522725
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Bruton's Tyrosine Kinase Suppresses Cancer Stemness and Promotes Carboplatin-induced Cytotoxicity Against Bladder Cancer Cells.
Pan Y; Chiu YH; Chiu SC; Cho DY; Lee LM; Wen YC; Whang-Peng J; Hsiao CH; Shih PH
Anticancer Res; 2020 Nov; 40(11):6093-6099. PubMed ID: 33109547
[TBL] [Abstract][Full Text] [Related]
16. MEK5/ERK5 signaling inhibition increases colon cancer cell sensitivity to 5-fluorouracil through a p53-dependent mechanism.
Pereira DM; Simões AE; Gomes SE; Castro RE; Carvalho T; Rodrigues CM; Borralho PM
Oncotarget; 2016 Jun; 7(23):34322-40. PubMed ID: 27144434
[TBL] [Abstract][Full Text] [Related]
17. Specific Expression of a New Bruton Tyrosine Kinase Isoform (p65BTK) in the Glioblastoma Gemistocytic Histotype.
Sala L; Cirillo G; Riva G; Romano G; Giussani C; Cialdella A; Todisco A; Virtuoso A; Cerrito MG; Bentivegna A; Grassilli E; Ardizzoia A; Bonoldi E; Giovannoni R; Papa M; Lavitrano M
Front Mol Neurosci; 2019; 12():2. PubMed ID: 30733667
[TBL] [Abstract][Full Text] [Related]
18. 5-fluorouracil resistant colon cancer cells are addicted to OXPHOS to survive and enhance stem-like traits.
Denise C; Paoli P; Calvani M; Taddei ML; Giannoni E; Kopetz S; Kazmi SM; Pia MM; Pettazzoni P; Sacco E; Caselli A; Vanoni M; Landriscina M; Cirri P; Chiarugi P
Oncotarget; 2015 Dec; 6(39):41706-21. PubMed ID: 26527315
[TBL] [Abstract][Full Text] [Related]
19. Melatonin synergizes the chemotherapeutic effect of 5-fluorouracil in colon cancer by suppressing PI3K/AKT and NF-κB/iNOS signaling pathways.
Gao Y; Xiao X; Zhang C; Yu W; Guo W; Zhang Z; Li Z; Feng X; Hao J; Zhang K; Xiao B; Chen M; Huang W; Xiong S; Wu X; Deng W
J Pineal Res; 2017 Mar; 62(2):. PubMed ID: 27865009
[TBL] [Abstract][Full Text] [Related]
20. Knockdown of PRDX2 sensitizes colon cancer cells to 5-FU by suppressing the PI3K/AKT signaling pathway.
Xu J; Zhang S; Wang R; Wu X; Zeng L; Fu Z
Biosci Rep; 2017 Jun; 37(3):. PubMed ID: 28432271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
